{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:19:24Z","timestamp":1790140764394,"version":"4.0.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The modified Mayo score (mMS) is a measure for ulcerative colitis (UC) disease activity. Recent US Food and Drug Administration guidance for moderately to severely active UC trials suggests that patients should have baseline mMS of 5\u20139 including an endoscopy score of at least 2, as opposed to the previous range of 4\u20139. This disclosure reports results from patients with UC with baseline mMS of 5\u20139 who received mirikizumab, a monoclonal antibody directed against the interleukin-23 p19 subunit, or placebo in the phase 3 LUCENT trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Mirikizumab was evaluated in the randomized, double-blind, placebo-controlled LUCENT-1 (NCT03518086) and LUCENT-2 (NCT03524092) trials, and the ongoing long-term LUCENT-3 (NCT03519945) trial, which use mMS 4\u20139. Analyses for patients with baseline mMS of 5\u20139 (excluding patients with mMS of 4) were conducted according to LUCENT trial statistical analysis plans. Categorical efficacy endpoints were summarized using proportions and confidence intervals. Continuous efficacy endpoints are presented as least-squares mean (standard error) changes from baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mirikizumab demonstrated efficacy for the primary endpoint of clinical remission and major secondary endpoints including clinical response, endoscopic improvement, histologic\u2013endoscopic mucosal improvement\/remission, bowel urgency remission, and corticosteroid-free remission. Importantly, mirikizumab exhibited greater improvements versus placebo in the Inflammatory Bowel Disease Questionnaire, fatigue, symptomatic remission, and work productivity. Finally, mirikizumab demonstrated long-term (104-week) sustained, durable efficacy across all studied endpoints. No new safety signals were identified during the 2-year follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Mirikizumab delivered significant clinical benefit for patients with baseline mMS of 5\u20139 and demonstrated a favorable safety profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otaf002","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T07:30:06Z","timestamp":1736321406000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-1224","authenticated-orcid":false,"given":"Bincy","family":"Abraham","sequence":"first","affiliation":[{"name":"Department of Medicine, Houston Methodist , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-1090","authenticated-orcid":false,"given":"Jianmin","family":"Wu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Gastroenterology & Hepatology Department, University Hospitals Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Melmed","sequence":"additional","affiliation":[{"name":"IM Gastroenterology, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-3758","authenticated-orcid":false,"given":"Ryan","family":"Ungaro","sequence":"additional","affiliation":[{"name":"Gastroenterology, Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Charabaty","sequence":"additional","affiliation":[{"name":"Gastroenterology, Johns Hopkins University School of Medicine , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moses","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Chan-Diehl","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Paulissen","sequence":"additional","affiliation":[{"name":"Syneos Health , Morrisville, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9894-8796","authenticated-orcid":false,"given":"Edward L","family":"Barnes","sequence":"additional","affiliation":[{"name":"Deptartment of Medicine, The University of North Carolina , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"Lewis Katz School of Medicine, Temple University , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, University of Chicago Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"4","key":"2025042103514608500_CIT0001","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ibd.20301","article-title":"Quality of life of patients with","volume":"14","author":"Irvine","year":"2008","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2025042103514608500_CIT0002","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1053\/j.gastro.2019.01.073","article-title":"P024 patient and healthcare provider views on ulcerative colitis treatment goals and quality of life: results of a global ulcerative colitis narrative survey","volume":"156","author":"Dubinsky","year":"2019","journal-title":"Gastroenterology."},{"key":"2025042103514608500_CIT0003","author":"United States Food and Drug Administration","year":"2016"},{"key":"2025042103514608500_CIT0004","author":"United States Food and Drug Administration","year":"2022"},{"key":"2025042103514608500_CIT0005","doi-asserted-by":"publisher","first-page":"17562848221136331","DOI":"10.1177\/17562848221136331","article-title":"Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program","volume":"15","author":"Sandborn","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"2025042103514608500_CIT0006","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev.med.60.051407.123757","article-title":"IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease","volume":"60","author":"Abraham","year":"2009","journal-title":"Annu Rev Med."},{"issue":"12","key":"2025042103514608500_CIT0007","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn\u2019s disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut."},{"key":"2025042103514608500_CIT0008","author":"European Medicines"},{"issue":"26","key":"2025042103514608500_CIT0009","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med."},{"key":"2025042103514608500_CIT0010","author":"Eli Lilly Nederland B.V. U","year":"2023"},{"key":"2025042103514608500_CIT0011","author":"Lilly USA L","year":"2023"},{"issue":"12","key":"2025042103514608500_CIT0012","doi-asserted-by":"publisher","first-page":"izae024","DOI":"10.1093\/ibd\/izae024","article-title":"Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"30","author":"Sands","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025042103514608500_CIT0013","author":"Research CfDEa, Research CfBEa","year":"2023"},{"issue":"1","key":"2025042103514608500_CIT0014","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"25","author":"Public Policy Committee ISoP","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"10","key":"2025042103514608500_CIT0015","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","article-title":"Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase III LUCENT studies","volume":"62","author":"Chua","year":"2023","journal-title":"Clin Pharmacokinet."},{"issue":"8","key":"2025042103514608500_CIT0016","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/(sici)1097-0258(19980430)17:8&lt;873::aid-sim779&gt;3.0.co;2-i","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med."},{"issue":"158","key":"2025042103514608500_CIT0017","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2307\/2276774","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc."},{"key":"2025042103514608500_CIT0018","volume-title":"Multiple Imputation for Nonresponse in Surveys. Wiley Series in Probability and Statistics","author":"Rubin","year":"1987"},{"issue":"5","key":"2025042103514608500_CIT0019","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"12","key":"2025042103514608500_CIT0020","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.crohns.2014.08.011","article-title":"Systematic review: histological remission in inflammatory bowel disease. Is \u201ccomplete\u201d remission the new treatment paradigm? An IOIBD initiative","volume":"8","author":"Bryant","year":"2014","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025042103514608500_CIT0021","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology."},{"issue":"11","key":"2025042103514608500_CIT0022","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/ecco-jcc\/jjaa110","article-title":"ECCO position paper: harmonization of the approach to ulcerative colitis histopathology","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"11","key":"2025042103514608500_CIT0023","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1016\/j.cgh.2019.12.011","article-title":"Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis","volume":"18","author":"Pai","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2025042103514608500_CIT0024","doi-asserted-by":"publisher","first-page":"e001115","DOI":"10.1136\/bmjgast-2023-001115","article-title":"Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis","volume":"10","author":"Dubinsky","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"issue":"3","key":"2025042103514608500_CIT0025","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"7 Suppl 6","key":"2025042103514608500_CIT0026","first-page":"11","article-title":"Risankizumab in patients with moderately to severely active ulcerative colitis in the phase 3 INSPIRE and COMMAND studies","volume":"20","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"12 Suppl 9","key":"2025042103514608500_CIT0027","first-page":"9","article-title":"Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE study","volume":"19","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"13","key":"2025042103514608500_CIT0028","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otaf002\/61372453\/otaf002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/2\/otaf002\/61372453\/otaf002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/2\/otaf002\/61372453\/otaf002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T07:52:21Z","timestamp":1745221941000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otaf002\/7945292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otaf002","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,8]]},"article-number":"otaf002"}}